Free shipping on all orders over $ 500

Aflibercept

Cat. No. M3849

All AbMole products are for research use only, cannot be used for human consumption.

Aflibercept Structure
Size Price Availability Quantity
1mg USD 800  USD800 In stock
2mg USD 1000  USD1000 In stock
5mg USD 1800  USD1800 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Aflibercept is a vascular epidermal growth factor (VEGF-A and PlGF) receptor inhibitor that inhibits the growth of neovascularization. It can be used to study a variety of diseases caused by ocular neovascularization. Aflibercept is a recombinant fusion protein consisting of vascular endothelial growth factor (VEGF)-binding portions from the extracellular domains of human VEGF receptors 1 and 2, that are fused to the Fc portion of the human IgG1 immunoglobulin.

Chemical Information
Molecular Weight 96896.92
Formula C4318H6788N1164O1304S32
CAS Number 862111-32-8
Storage -80°C for long term
References

[1] María Rodríguez-Remírez, et al. Neuroendocrinology . Strong Antitumor Activity of Bevacizumab and Aflibercept in Neuroendocrine Carcinomas: In-Depth Preclinical Study

[2] Lisa-Marie Muellerleile, et al. Res Vet Sci. In-vitro binding analysis of anti-human vascular endothelial growth factor antibodies bevacizumab and aflibercept with canine, feline, and equine vascular endothelial growth factor

[3] Charlotte V Fischer, et al. Invest Ophthalmol Vis Sci. The Antiproliferative Effect of Bevacizumab on Human Tenon Fibroblasts Is Not Mediated by Vascular Endothelial Growth Factor Inhibition

[4] Sarwar S, et al. Cochrane Database Syst Rev. Aflibercept for neovascular age-related macular degeneration.

Related VEGFR/PDGFR Products
Conbercept

Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc.

SU5208 

SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).

VEGFR-IN-1 

VEGFR-IN-1 is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively.

(Z)-Orantinib

(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively.

(Rac)-SAR131675 

(Rac)-SAR131675 is the racemate of SAR131675.

  Catalog
Abmole Inhibitor Catalog




Keywords: Aflibercept supplier, VEGFR/PDGFR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.